NGM Bio
is a California-based clinical-stage biopharmaceutical company that researches and develops novel therapeutics for treating cardio-metabolic and liver diseases... Read moreNGM Bio
is a California-based clinical-stage biopharmaceutical company that researches and develops novel therapeutics for treating cardio-metabolic and liver diseases... Read more
News
Sep 08, 2025
centralcharts
Press Release: NGM Bio : Equity Litigation Group LLP Announces Pendency and Proposed Settlement of Stockholder Class Action for All Record Holders and Beneficial Holders of Shares of NGM Biopharmaceuticals, Inc., Common Stock
Jul 25, 2025
Law 360
NGM Bio: NGM Biopharma Investors Take $6M Deal To End Sale Suit
May 12, 2025
The Business Journals: San Francisco Business Times
NGM Bio: Pioneering biotech NGM to cut 75% of workforce as CEO departs
Feb 25, 2025
Medthority
NGM Bio: First Patient Dosed in EMERALD Phase II Study
Dec 23, 2024
The Business Journals: Raleigh/Durham
NGM Bio: Stealthy drug company forms with $600 million deal
Dec 19, 2024
GlobalNewswire
Press Release: NGM Bio : NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/-Klotho Agonist Drug Candidate
Jul 17, 2024
PharmaLive
NGM Bio: Newly private NGM Bio raises $122M for registrational PSC study
Jul 17, 2024
The Business Journals: San Francisco Business Times
NGM Bio: Months after going private, Peninsula biotech raises $122 million to push 2 drugs toward finish line
Jul 17, 2024
Endpoints News
NGM Bio: Three months after delisting, NGM Bio is back with $122M for slimmed-down pipeline
Apr 05, 2024
MarketScreener
NGM Bio: NGM Bio Announces Closing of Tender Offer
NGM Bio Competitors
1
2
3
4
5
6
7
8
9
10